Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos de Oncologia | EligiMed
Ensayos clinicos
1.365 ensayos encontrados
Activo, no recluta
Fase 2
ClinicalTrials.gov
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)
INTERVENTIONAL
Inicio: 9 de ene de 2024
ID: NCT06105632
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)
INTERVENTIONAL
Inicio: 20 de jul de 2018
ID: NCT03512197
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
INTERVENTIONAL
Inicio: 1 de jun de 2016
ID: NCT02767804
Completado
Fase 2
ClinicalTrials.gov
A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
INTERVENTIONAL
Inicio: 14 de nov de 2017
ID: NCT03200717
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
INTERVENTIONAL
Inicio: 9 de abr de 2015
ID: NCT02312258
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
INTERVENTIONAL
Inicio: 25 de abr de 2016
ID: NCT02603432
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
INTERVENTIONAL
Inicio: 8 de jun de 2020
ID: NCT04251533
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
INTERVENTIONAL
Inicio: 16 de jul de 2014
ID: NCT02181413
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
INTERVENTIONAL
Inicio: 30 de abr de 2019
ID: NCT03911869
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
INTERVENTIONAL
Inicio: 25 de ago de 2020
ID: NCT04498117
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
INTERVENTIONAL
Inicio: 5 de abr de 2017
ID: NCT02972840
Completado
Fase 2
ClinicalTrials.gov
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
INTERVENTIONAL
Inicio: 28 de dic de 2017
ID: NCT02684058
Activo, no recluta
Fase 3
ClinicalTrials.gov
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
INTERVENTIONAL
Inicio: 21 de dic de 2020
ID: NCT04607421
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
INTERVENTIONAL
Inicio: 2 de dic de 2021
ID: NCT05152147
Activo, no recluta
Fase 2
ClinicalTrials.gov
A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
INTERVENTIONAL
Inicio: 23 de sept de 2020
ID: NCT04557449
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 18 de dic de 2018
ID: NCT03729245
Activo, no recluta
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
INTERVENTIONAL
Inicio: 3 de mar de 2023
ID: NCT05654623
Completado
Fase 2
ClinicalTrials.gov
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
INTERVENTIONAL
Inicio: 29 de ago de 2017
ID: NCT03056755
Terminado
Fase 2
ClinicalTrials.gov
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00372996
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 16 de mar de 2018
ID: NCT03447769
Anterior
1
2
3
...
69
Siguiente
Filtros